Evidence map›Paper›PMID 40973539›Full record

ArticleNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2025

TNFR2 signaling shapes the sex-specific remyelinating properties of microglia after experimental stroke.

Stefano Raffaele, Francesca Carolina Mannella, Estrid Thougaard, Pernille Vinther Nielsen, Morten Blickfeldt-Eckhardt, Eva Tolosa, Justine Münsterberg, Tim Magnus, Jens D Mikkelsen, Mathias Gelderblom and 5 more

Abstract read
In one paragraph

Article in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Stefano RaffaeleDepartment of Pharmaceutical Sciences, Università degli Studi di Milano, 20133, Milan, Italy; Department of Neurobiology Research, Institute of Molecular Medicine, University of Southern Denmark, 5230, Odense M, Denmark.
Francesca Carolina MannellaDepartment of Pharmaceutical Sciences, Università degli Studi di Milano, 20133, Milan, Italy.
Estrid ThougaardDepartment of Neurobiology Research, Institute of Molecular Medicine, University of Southern Denmark, 5230, Odense M, Denmark.
Pernille Vinther NielsenDepartment of Neurobiology Research, Institute of Molecular Medicine, University of Southern Denmark, 5230, Odense M, Denmark.
Morten Blickfeldt-EckhardtDepartment of Anaesthesiology, Lillebaelt Hospital Vejle, 7100, Vejle, Denmark; Department of Regional Health Research, University of Southern Denmark, 5230, Odense M, Denmark.
Eva TolosaDepartment of Immunology, University Medical Center Hamburg-Eppendorf, 20246, Hamburg, Germany; Hamburg Center for Translational Immunology, University Medical Center Hamburg-Eppendorf, 20246, Hamburg, Germany.
Justine MünsterbergDepartment of Neurology, University Medical Center Hamburg-Eppendorf, 20246, Hamburg, Germany.
Tim MagnusDepartment of Neurology, University Medical Center Hamburg-Eppendorf, 20246, Hamburg, Germany.
Jens D MikkelsenDepartment of Neurobiology Research, Institute of Molecular Medicine, University of Southern Denmark, 5230, Odense M, Denmark; Neurobiology Research Unit, University Hospital Copenhagen, Rigshospitalet, 2100, Copenhagen, Denmark; Department of Neuroscience, University of Copenhagen, 2200, Copenhagen, Denmark.
Mathias GelderblomDepartment of Neurology, University Medical Center Hamburg-Eppendorf, 20246, Hamburg, Germany.
Helle Hvilsted NielsenDepartment of Neurobiology Research, Institute of Molecular Medicine, University of Southern Denmark, 5230, Odense M, Denmark; Department of Clinical Research, BRIDGE-Brain Research Inter Disciplinary Guided Excellence, University of Southern Denmark, 5000, Odense C, Denmark; Department of Neurology, Odense University Hospital, 5000, Odense C, Denmark.
Bettina Hjelm ClausenDepartment of Neurobiology Research, Institute of Molecular Medicine, University of Southern Denmark, 5230, Odense M, Denmark; Department of Neurology, Odense University Hospital, 5000, Odense C, Denmark.
Roberta BrambillaThe Miami Project to Cure Paralysis, University of Miami Miller School of Medicine, 33136, Miami FL, USA.
Marta FumagalliDepartment of Pharmaceutical Sciences, Università degli Studi di Milano, 20133, Milan, Italy. Electronic address: marta.fumagalli@unimi.it.
Kate Lykke LambertsenDepartment of Neurobiology Research, Institute of Molecular Medicine, University of Southern Denmark, 5230, Odense M, Denmark; Department of Clinical Research, BRIDGE-Brain Research Inter Disciplinary Guided Excellence, University of Southern Denmark, 5000, Odense C, Denmark; Department of Neurology, Odense University Hospital, 5000, Odense C, Denmark. Electronic address: klambertsen@health.sdu.dk.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Microglial tumor necrosis factor receptor 2 (TNFR2) has emerged as a critical modulator of neuroinflammation and repair following ischemic stroke. Here, we investigated the sex-specific role of TNFR2 in regulating microglial responses during the acute and subacute phases after stroke. Using a conditional knockout model, we found that TNFR2 ablation in microglia exerted opposite effects on morphology, reactivity, and phagocytic capacity in female compared to male mice at day 5 post-stroke. In females, TNFR2 deletion impaired microglial reactivity and myelin debris clearance, reduced oligodendrocyte maturation, and worsened motor and cognitive recovery. In contrast, TNFR2 ablation in males produced milder and occasionally opposing effects, without affecting functional outcomes. Analysis of cerebrospinal fluid from stroke patients revealed a positive association between TNFR2 and microglial phagocytosis markers (TREM2, Galectin-3), particularly in females, which may be useful to track microglial pro-regenerative state during rehabilitation and therapy. These findings identify TNFR2 as a sex-dependent regulator of microglial function and highlight its potential as a therapeutic target for enhancing post-stroke recovery, especially in women.

Indexed as

MicrogliaMyelin SheathReceptors, Tumor Necrosis Factor, Type IISex CharacteristicsSignal TransductionStrokeAnimalsFemaleHumansInfarction, Middle Cerebral ArteryMaleMembrane GlycoproteinsMiceMice, Inbred C57BLMice, KnockoutPhagocytosisMembrane GlycoproteinsReceptors, ImmunologicReceptors, Tumor Necrosis Factor, Type IITnfrsf1b protein, mouseTrem2 protein, mouseMicrogliaPhagocytosisRemyelinationStrokeTNFR2

Identifiers

PMID40973539
PMCPMC12664556

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.